Abstract: The present application relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 1500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C.

Abstract: The present invention relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C.

Abstract: The present invention provides nucleic acid products and corresponding methods for screening a biological sample for the presence of a respiratory infection-causing microorganism.

Abstract: The present invention provides antigens, for use in the treatment or prevention of C. burnetii infection. Also provided are nucleic acids encoding such antigens, and antibodies raised against such antigens.

Abstract: The present invention provides a viral vector or bacterial vector, said vector comprising a nucleic acid sequence encoding a Crimean-Congo Haemorrhagic Fever Virus (CCHFV) glycoprotein or antigenic fragment thereof; wherein said vector is capable of inducing an immune response in a subject. The present invention also provides compositions and uses of the vector in methods of medical treatment.

Abstract: There is provided an antigenic composition comprising (a) a first mycobacterial antigenic polypeptide or a first mycobacterial polynucleotide; and (b) a second mycobacterial antigenic polypeptide or a second mycobacterial polynucleotide; wherein: (i) said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1 or 7, or a fragment thereof having at least 7 consecutive amino acids thereof; (ii) said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide; (iii) said second mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 5, or a fragment thereof having at least 7 consecutive amino acids thereof; and (iv) said second mycobacterial polynucleotide comprises a polynucleotide sequence encoding said second mycobacterial polypeptid

Abstract: The present invention provides antibodies, for use in the treatment, suppression prevention of Filovirus disease, particularly Ebola virus disease. Also provided immunogens for use in eliciting such antibodies.

Abstract: The present invention provides an antigenic composition for use as a mycobacterial vaccine, said composition comprising (i) a first mycobacterial antigenic polypeptide, wherein said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 6, 12, 2, 18, 8, 10, 16, 4, or a fragment thereof having at least 50 consecutive amino acids thereof; or (ii) a first mycobacterial polynucleotide, wherein said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide, or wherein said first mycobacterial polynucleotide comprises a polynucleotide sequence selected from SEQ ID NO: 5, 11, 1, 17, 7, 9, 15, 3.

Abstract: The present invention relates to recombinant Clostridium difficile antigens based on a polypeptide, consisting of or comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence consisting of residues 1500-700 of a C. difficile Toxin A sequence or a C. difficile Toxin B sequence; though with the proviso that the polypeptide does not include one or more Repeat Unit (RU) located between amino acid residues 1851-2710 of C. difficile Toxin A and/or residues 1853-2366 of a C. difficile Toxin B protein that consists of or comprises a first amino acid sequence and a second amino acid. Also provided is the use of said antigens for the prevention/treatment/suppression of Clostridium difficile infection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/treatment/suppression of CDI.

Abstract: This invention relates to the detection of carbapenem-resistant bacteria and the diagnosis of carbapenem-resistant bacteria infection. More specifically, the invention relates to new primers and probes for particular carbapenemase genes, which enable the accurate detection of carbapenem-resistant bacteria.

Abstract: The present disclosure relates to the field of medicinal chemistry and more particularly to the development of antimicrobial compounds. The disclosure relates to the synthesis and characterization of compounds comprising aromatic radical or an aliphatic radical, an alkyl amine and amino acid moiety wherein said compounds exhibit antimicrobial activity against various drug-sensitive and drug-resistant pathogenic 10 microorganisms.

Abstract: The present invention relates to unique CDR3 amino acid sequences, and to antibodies comprising said sequences. Also provided are therapeutic applications of said antibodies for use in treating or preventing influenza infection, diagnostic applications of said antibodies for use in detecting influenza virus, potency testing of influenza virus vaccines, and screening applications of said antibodies for use in designing a universal influenza vaccine.

Abstract: An improved monocyte activation test is described that is better able to detect non-endotoxin pyrogens in medical products, in which a sample is incubated with a monocyte-containing reagent in an assay system comprising at least one surface comprising polypropylene. The invention also concerns assay systems for use in these tests that include at least one microtiter well having at least one interior surface comprising polypropylene and having a shape such that monocyte-containing reagent is concentrated in the well to provide greater cell to cell contact. The invention also relates to a diagnostic kit that can be used to test for the presence of non-endotoxin pyrogens in a sample.

Abstract: The present disclosure relates to polyamine conjugates, its isomers, prodrugs and pharmaceutically acceptable salts thereof. The present disclosure also relates to process of preparation of polyamine conjugates, its stereoisomers, prodrugs, pharmaceutically acceptable salts thereof, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases mediated by microbes.

Abstract: This invention relates to the detection and diagnosis of tuberculosis. More specifically, the invention relates to new biomarkers and combinations thereof that enable the accurate detection and diagnosis of tuberculosis.

Abstract: A fluid collection device comprising an elongate container having an opening at one end, and a swab that is insertable into the container through said opening, wherein: the swab comprises an absorbent collector, for acquiring a fluid sample in use; and the internal cross-sectional area of the container becomes smaller in a direction away from the opening, the internal cross-sectional area becoming sufficiently small so as to cause the absorbent collector to be radially compressed as the swab is inserted into the container in use, thereby causing the absorbent collector to release at least some of the fluid sample held therein. The swab may further comprise a shaft, the absorbent collector being at or near a distal end of the shaft, and a closure being at or near a proximal end of the shaft, the closure being adapted to engage with the container and to close the opening of the container with the absorbent collector inside the container.

Abstract: This invention relates to adeno-associated viral (AVV) vectors, to producer cell lines for the production of AAV vectors and to methods of producing such vectors. More specifically, the invention relates to producer cell lines adapted to increase the titre of said vectors and methods of producing AAV vectors using said producer cell lines.

Abstract: An instrument for detecting radiation is provided, which comprises an inner core housing a neutron detector, and an outer core comprising a neutron-moderating material, the instrument further including at least one elongate thermal neutron guide located within the outer core and having an inner end that terminates proximal to the neutron detector. In use, the elongate thermal neutron guide channels thermal neutrons towards the neutron detector. Also provided is a method for using said instrument.

Abstract: The present invention relates to recombinant Clostridium difficile antigens based on a polypeptide, consisting of or comprising an amino acid sequence having at least 80% sequence identity with an amino acid sequence consisting of residues 1500-700 of a C. difficile Toxin A sequence or a C. difficile Toxin B sequence; though with the proviso that the polypeptide does not include one or more Repeat Unit (RU) located between amino acid residues 1851-2710 of C. difficile Toxin A and/or residues 1853-2366 of a C. difficile Toxin B protein that consists of or comprises a first amino acid sequence and a second amino acid. Also provided is the use of said antigens for the prevention/treatment/suppression of Clostridium difficile infection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/treatment/suppression of CDI.

Abstract: An instrument for detecting radiation is provided, which comprises an inner core housing a neutron detector, and another core comprising a neutron-moderating material, the instrument further including at least one elongate thermal neutron guide located within the outer core and having an inner end that terminates proximal to the neutron detector. In use, the elongate thermal neutron guide channels thermal neutrons towards the neutron detector. Also provided is a method for using said instrument.